Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Current Assets (2016 - 2025)

Historic Current Assets for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to $168.5 million.

  • UroGen Pharma's Current Assets fell 4288.45% to $168.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $168.5 million, marking a year-over-year decrease of 4288.45%. This contributed to the annual value of $276.1 million for FY2024, which is 6321.39% up from last year.
  • Latest data reveals that UroGen Pharma reported Current Assets of $168.5 million as of Q3 2025, which was down 4288.45% from $196.9 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Current Assets ranged from a high of $295.1 million in Q3 2024 and a low of $81.3 million during Q2 2023
  • In the last 5 years, UroGen Pharma's Current Assets had a median value of $160.5 million in 2022 and averaged $168.5 million.
  • As far as peak fluctuations go, UroGen Pharma's Current Assets soared by 24299.48% in 2024, and later plummeted by 4288.45% in 2025.
  • Quarter analysis of 5 years shows UroGen Pharma's Current Assets stood at $114.4 million in 2021, then grew by 12.69% to $128.9 million in 2022, then skyrocketed by 31.25% to $169.2 million in 2023, then skyrocketed by 63.21% to $276.1 million in 2024, then plummeted by 38.96% to $168.5 million in 2025.
  • Its Current Assets was $168.5 million in Q3 2025, compared to $196.9 million in Q2 2025 and $237.2 million in Q1 2025.